About MAP Pharmaceuticals (NASDAQ:MAPP)
MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions
What is MAP Pharmaceuticals' stock symbol?
MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP."
Who are some of MAP Pharmaceuticals' key competitors?
Some companies that are related to MAP Pharmaceuticals include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Microsoft (MSFT), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has MAP Pharmaceuticals been receiving favorable news coverage?
News coverage about MAPP stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MAP Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the healthcare company an impact score of 47.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of MAP Pharmaceuticals?
Shares of MAPP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact MAP Pharmaceuticals?
MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581.
MarketBeat Community Rating for MAP Pharmaceuticals (MAPP)MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAPP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAPP will underperform the S&P 500 over the long term. You may vote once every thirty days.
MAP Pharmaceuticals (NASDAQ:MAPP) Analyst Ratings History
(Data available from 4/22/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
MAP Pharmaceuticals (NASDAQ:MAPP) Earnings History and Estimates Chart
MAP Pharmaceuticals (NASDAQ MAPP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
MAP Pharmaceuticals (NASDAQ:MAPP) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
MAP Pharmaceuticals (NASDAQ MAPP) Insider Trading and Institutional Ownership History
MAP Pharmaceuticals (NASDAQ MAPP) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
MAP Pharmaceuticals (NASDAQ MAPP) News Headlines
No headlines for this company have been tracked by MarketBeat.com
MAP Pharmaceuticals (NASDAQ:MAPP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MAP Pharmaceuticals (NASDAQ:MAPP) Income Statement, Balance Sheet and Cash Flow Statement
MAP Pharmaceuticals (NASDAQ MAPP) Stock Chart for Sunday, April, 22, 2018